As of 2024-09-19, the EV/EBITDA ratio of Alnylam Pharmaceuticals Inc (ALNY) is 241.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Alnylam's latest enterprise value is 35,121.19 mil USD. Alnylam's TTM EBITDA according to its financial statements is 145.60 mil USD. Dividing these 2 quantities gives us the above Alnylam EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 32.4x - 36.3x | 34.3x |
| Forward P/E multiples | 22.4x - 65.5x | 44.0x |
| Fair Price | 24.98 - 73.86 | 43.98 |
| Upside | -90.9% - -73.0% | -83.9% |
| Date | EV/EBITDA |
| 2024-09-18 | 241.22 |
| 2024-09-17 | 242.37 |
| 2024-09-16 | 238.76 |
| 2024-09-13 | 234.27 |
| 2024-09-12 | 231.15 |
| 2024-09-11 | 231.30 |
| 2024-09-10 | 226.28 |
| 2024-09-09 | 223.59 |
| 2024-09-06 | 217.96 |
| 2024-09-05 | 222.11 |
| 2024-09-04 | 223.57 |
| 2024-09-03 | 224.14 |
| 2024-08-30 | 231.99 |
| 2024-08-29 | 253.44 |
| 2024-08-28 | 247.87 |
| 2024-08-27 | 247.48 |
| 2024-08-26 | 237.68 |
| 2024-08-23 | 240.77 |
| 2024-08-22 | 244.90 |
| 2024-08-21 | 246.52 |
| 2024-08-20 | 247.93 |
| 2024-08-19 | 242.39 |
| 2024-08-16 | 236.89 |
| 2024-08-15 | 232.00 |
| 2024-08-14 | 232.17 |
| 2024-08-13 | 236.35 |
| 2024-08-12 | 238.60 |
| 2024-08-09 | 238.01 |
| 2024-08-08 | 238.84 |
| 2024-08-07 | 229.77 |
| 2024-08-06 | 231.88 |
| 2024-08-05 | 234.03 |
| 2024-08-02 | 240.25 |
| 2024-08-01 | 237.21 |
| 2024-07-31 | 209.75 |
| 2024-07-30 | 206.53 |
| 2024-07-29 | 208.71 |
| 2024-07-26 | 207.44 |
| 2024-07-25 | 210.12 |
| 2024-07-24 | 208.88 |
| 2024-07-23 | 206.95 |
| 2024-07-22 | 208.10 |
| 2024-07-19 | 210.07 |
| 2024-07-18 | 209.08 |
| 2024-07-17 | 212.00 |
| 2024-07-16 | 220.65 |
| 2024-07-15 | 226.25 |
| 2024-07-12 | 230.07 |
| 2024-07-11 | 230.52 |
| 2024-07-10 | 227.65 |